Cannabis Research
After 50 Years, U.S. Opens The Door To More Cannabis Crops For Scientists, by Will Stone, NPR, May 30, 2021
An Archaeology of Marijuana, by Stephen Nash, Sapiens, October 16, 2020
Cannabis as entheogen: survey and interview data on the spiritual use of cannabis, by Petter Grahl Johnstad, Journal of Cannabis Research, September 22, 2020
New Research Reveals Why Cannabis Helps PTSD Sufferers, by Emily Earlenbaugh, Forbes, September 17, 2020
Cannabis And Ketamine: Is There A Risk Of Interaction?, by Kate-Madonna Hindes, The Fresh Toast, June 22, 2020
Psychiatrist Explores Possible Benefits Of Treating PTSD With Ecstasy Or Cannabis, by Terry Gross, NPR, June 22, 2020
Is Cannabis a Psychedelic Drug?, by Barbara E. Bauer, MS, Psychedelic Science Review, October 31, 2019
Other Psychedelics Research
Ketamine
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A., Jr (2010). The Journal of clinical psychiatry, 71(12), 1605–1611.
Efficacy of ketamine therapy in the treatment of depression. Mandal, S., Sinha, V. K., & Goyal, N. (2019). Indian journal of psychiatry, 61(5), 480–485.
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., & Mathew, S. J. (2013). The American journal of psychiatry, 170(10), 1134–1142.
Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives. Shin, C., & Kim, Y. K. (2020). Psychiatry investigation, 17(3), 181–192
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., Drevets, W. C., & Van Nueten, L. (2016). Biological psychiatry, 80(6), 424–431.
Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Zheng, W., Zhou, Y. L., Liu, W. J., Wang, C. Y., Zhan, Y. N., Li, H. Q., Chen, L. J., Li, M. D., & Ning, Y. P. (2018). Journal of psychiatric research, 106, 61–68.
Psilocybin Research
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. Barba, T., Buehler, S., Kettner, H., Radu, C., Cunha, B., Nutt, D., . . . Carhart-Harris, R. BJPsych Open. 2022.
Increased global integration in the brain after psilocybin therapy for depression. Daws, R.E., Timmermann, C., Giribaldi, B. et al. Nature Medicine. 2022.
Therapeutic use of psilocybin: Practical considerations for dosing and administration. MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. Frontiers in Psychiatry. 2022.
Therapeutic effect of psilocybin in addiction: A systematic review. van der Meer Pim B., Fuentes Juan J., Kaptein Ad A., Schoones Jan W., de Waal Marleen M., Goudriaan Anneke E., Kramers Kees, Schellekens Arnt, Somers Metten, Bossong Matthijs G., Batalla Albert. Frontiers in Psychiatry. 2023.
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Kelmendi B, Kichuk SA, DePalmer G, Maloney G, Ching THW, Belser A, Pittenger C. Heliyon. 2022.
Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness. MacLean KA, Johnson MW, Griffiths RR. J Psychopharmacol. 2011.